TC
CLVS

TFS Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

TFS Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,744
Closed -$836K – 1691
2013
Q3 		$836K Buy
+13,744
New +$975K 0.04% 652

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TFS Capital's CLVS Position: Q4 2013 in Review

TFS Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2013, closing a stake of 13,744 shares — an estimated $836K sold.

TFS Capital first reported a position in CLVS in Q3 2013 and held it in 1 quarter. The position peaked at $836K in Q3 2013. 112 funds tracked by Wall St. Rank hold CLVS as of Q4 2013.

  • TFS Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2013 after selling out during the quarter.
  • TFS Capital sold 13,744 Clovis Oncology, Inc. shares in Q4 2013, an estimated $836K.
  • TFS Capital first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 1 quarter.
  • TFS Capital's Clovis Oncology, Inc. position peaked at $836K in Q3 2013.
  • 112 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2013.

Based on TFS Capital's 13F filing for Q4 2013, filed 7 Feb 2014.